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Background-—Limited data exist on the economic implications of stroke among patients with atrial ﬁbrillation (AF). This study
assesses the impact of AF on healthcare costs associated with ischemic stroke (IS), hemorrhagic stroke (HS), or transient ischemic
attack (TIA).
Methods and Results-—A retrospective analysis of MarketScan claims data (2005-2011) for AF patients ≥18 years old with ≥1
inpatient claim for stroke, or ≥1 ED or inpatient claim for TIA as identiﬁed by ICD-9-CM codes who had ≥12 months continuous
enrollment prior to initial stroke. Initial event- and stroke-related costs 12 months post-index were compared among patients with
AF and without AF. Adjusted costs were estimated, controlling for demographics, comorbidities, anticoagulant use, and baseline
resource use. Data from 23 807 AF patients and 136 649 patients without AF were analyzed. Unadjusted mean cost of the index
event was $20 933 for IS, $59 054 for HS, $8616 for TIA hospitalization, and $3395 for TIA ED visit. After controlling for potential
confounders, adjusted mean incremental costs (index plus 12-month post-index) for AF patients were higher than those for non-AF
patients by: $4726, $7824, and $1890 for index IS, HS, TIA (identiﬁed by hospitalization), respectively, and $1700 for TIA
(identiﬁed by ED) (all P<0.01). In multivariate regression analysis, AF was associated with a 20% (IS), 13% (HS), and 18% (TIA)
increase in total stroke-related costs.
Conclusion-—Stroke-related care for IS, HS, and TIA is costly, especially among individuals with AF. Reducing the risk of AF-related
stroke is important from both clinical and economic standpoints. (J Am Heart Assoc. 2013;2:e000479 doi: 10.1161/JAHA.113.
000479)
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S
troke among atrial ﬁbrillation (AF) patients has been
shown to be associated with increased severity, func-
tional disability, and mortality compared with patients without
AF.
1 While stroke-related costs have been estimated among a
general population,
2 limited data exist on the economic
implications of stroke among patients with AF. In this
retrospective study, we estimate the cost of ischemic stroke
(IS), hemorrhagic stroke (HS), and transient ischemic attack
(TIA) among patients with AF versus those without AF from a
third-party payer perspective. These data will provide a
baseline estimate on the economic burden of stroke to
inform future cost-beneﬁt evaluation of interventions aimed at
preventing stroke in AF patients.
Methods
Data Source
This study used administrative claims data from the Truven
Health Analytics MarketScan
  Research Databases (Com-
mercial and Medicare Supplemental), 2005-2011. The com-
mercial database includes data from 150 contributing large
self-insured employers. The Medicare Supplemental database
contains the healthcare experience of individuals with Medi-
care supplemental insurance paid by employers. Approxi-
mately 40 million lives were analyzed, allowing for a nationally
representative sample of Americans with employer-provided
health insurance.
Patient Selection
We identiﬁed adult patients (≥18 years of age) with at least 1
primary inpatient diagnosis of stroke or TIA (International
Classiﬁcation Modiﬁcation [ICD-9-CM]: 430.xx, 431.xx, 432.xx
for hemorrhagic; 433.01, 433.11, 433.31, 434.xx for ische-
mic; 435.8, 435.9 for TIA)
2–6 or at least 1 emergency
department diagnosis of TIA between January 1, 2006 and
November 1, 2011. The date of the ﬁrst identiﬁed stroke or
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ORIGINAL RESEARCHTIA diagnosis constituted the index date. Patients could not
have had a stroke or TIA diagnosis in the 12 months prior to
the index stroke (ie, to ensure a “baseline period” without
stroke or TIA) and were required to be continuously eligible for
12 months prior to the index stroke event.
Presence of AF was based on ≥1 inpatient or ≥2 outpatient
claims (separated by <1 year) associated with an AF diagno-
sis (ICD-9-CM: 427.31)
7,8 in the baseline period and up to
3 months after index stroke event to allow inclusion of
patients who were identiﬁed to have AF after stroke
occurrence.
Study Measures
The following baseline demographic and clinical characteris-
tics were evaluated—age, sex, geographic region, metropol-
itan statistical area, year of index stroke diagnosis, type of
stroke or TIA, comorbidities, use of oral anticoagulants (ie,
Table 1. Baseline Characteristics
Characteristic Overall AF Cohort Non-AF Cohort P Value*
Number of subjects 160 456 23 807 136 649
Age, y
Mean, SD 69 (14.8) 77 (11.6) 67 (14.8) <0.0001
Age group
<55, N (%) 29 572 (18.4) 1048 (4.4) 28 560 (20.9)
55 to 64, N (%) 39 376 (24.6) 3285 (13.8) 36 075 (26.4)
65+, N (%) 91 508 (57.0) 19 474 (81.8) 72 014 (52.7)
Female, % 51.5 50.7 51.6 0.0121
Geographic Region, %
Northeast 12.8 15.3 12.4 <0.0001
North Central 34.6 35.3 34.4
West 17.1 19.7 16.7
South 35.3 29.5 36.3
Unknown 0.2 0.3 0.2
Metropolitan statistical area, % 84.0 84.0 82.9 <0.0001
Stroke Type, %
Ischemic 49.9 59.9 48.2 <0.0001
TIA 36.2 27.3 37.8
Hemorrhagic 13.9 12.8 14.1
Type of Hemorrhagic Stroke
†,%
Subarachnoid 25.3 8.9 27.9
Intracerebral 51.2 58.4 50.0
Other and unspecified intracranial 23.5 32.6 22.0
Selected Comorbidities (>5% frequency, %)
Chronic obstructive pulmonary disease 9.7 15.0 8.8 <0.0001
Congestive heart failure (excluding left ventricular) 9.0 24.1 6.4 <0.0001
Diabetes mellitus 24.6 26.9 24.2 <0.0001
Hypertension 51.2 62.1 49.3 <0.0001
Malignancy 13.9 19.1 13.0 <0.0001
Peripheral vascular disease 9.6 15.2 8.6 <0.0001
OAC use, % 10.2 43.5 4.4 <0.0001
AF indicates atrial ﬁbrillation; OAC, oral anticoagulant; TIA, transient ischemic attack; SD, standard deviation.
*Fisher’s exact or Wilcoxon test.
†Type of hemorrhagic stroke was not tested.
Source: Truven MarketScan
  Research Databases January 1, 2005 to December 31, 2011.
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Hwarfarin, dabigatran, and rivaroxaban), inpatient and ED
resource use, and duration of follow-up.
Outcomes included index hospitalization length of stay
(LOS), index event costs (all costs occurring throughout the
timeframe of the index hospitalization or ED visit), hospital-
ization rates within 30 days of index event, stroke-related
hospitalization rates 12 months post-index, and stroke-
related costs 12 months post-index for all components of
medical care. Stroke-related costs and hospitalizations were
required to list a stroke/TIA ICD-9-CM code.
Costs data reﬂect the total gross payments to all providers
associated with a given medical event. Total stroke-related
costs were derived by summing all payments associated with
a stroke/TIA admission (based on primary or any ICD-9-CM
diagnosis code) over the 12-month follow-up period for all
places of service (eg, inpatient, outpatient, emergency
department, skilled nursing facility, home health care, durable
medical equipment). Stroke-related laboratory and pharmacy
costs (ie, the presence of select medications, including
anticoagulants such as warfarin, dabigatran, and rivaroxaban,
as well as antiplatelets and rate/rhythm control medications)
were included in the calculation of total costs.
Follow-up analysis included those patients who were
continuously enrolled for 12 months following the index event.
Statistical Analyses
We compared adjusted index event LOS and stroke-related
cost between patients with and without AF using a general-
ized linear model with a negative binomial distribution and a
log link, controlling for age, sex, geography, year of index
diagnosis, selected comorbidities (based on >5% frequency),
oral anticoagulant (OAC) use, and baseline hospital and ED
use. Given common characteristics observed in healthcare
cost data, such as a highly skewed distribution from the small
percentage of patients with extremely high expense rates, the
generalized linear model is highly recommended for models
using administrative claims data.
9 Regression coefﬁcients
from the generalized linear model help to quantify the
relationship between 12-month stroke-related costs and the
selected patient characteristics (eg, when exponentiated
using a base of e, the coefﬁcient represents a percentage
increase/decrease in costs compared to patients without the
characteristic). Adjusted stroke-related hospitalization rates
were estimated using a logistic regression controlling for the
same covariates included in the generalized linear model.
Results
We identiﬁed 160 456 patients with stroke or TIA, 23 807
(14.8%) of whom had AF (Table 1). Of the AF patients, 43.5%
were on an oral-anticoagulant in the baseline period. There
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E
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R
C
Hwere differences in terms of demographic and clinical
characteristics between the AF and non-AF groups. In the
AF cohort, mean age was 77 years (11.6) compared to a
mean age of 67 years (14.8) in the non-AF cohort (P<0.01)
(Table 1). Prevalence of selected comorbidities was also
higher in the AF cohort (P<0.01).
In the overall sample, 49.9% of patients had IS, 13.9% had
HS, and 36.2% had TIA (12.2% identiﬁed with ED; 24.0%
identiﬁed with hospitalization). Compared to the non-AF
cohort, the AF cohort had higher rates of IS, intracerebral
hemorrhage, and other intracranial hemorrhage and lower
rates of TIA and subarachnoid hemorrhage (Table 1).
Among IS and TIA patients, the AF cohort had longer index
hospitalization LOS than the non-AF cohort (8.3 versus 7.9 for
IS; 4.1 versus 3.4 for TIA), but the opposite was true for HS
patients (10.7 versus 14.1 days). Among patients surviving
the index event, hospitalization within 30 days of discharge
was signiﬁcantly more common among AF patients, regard-
less of index stroke type (OR=1.248 P<0.05 for IS; OR=1.424
P<0.05 for HS; OR=1.425 P<0.05 for TIA).
Unadjusted mean cost of index event was $20 933
($37 413) for IS, $59 054 ($99 512) for HS, $8616
(10 812) for TIA with index hospitalization, and $3395
(3862) for TIA with index ED visit (Table 2). Adjusted mean
incremental costs (index plus 12-month post-index) for AF
patients were signiﬁcantly higher than those for non-AF
patients by: $4726, $7824, and $1890 for index IS, HS, TIA
(identiﬁed by hospitalization), respectively, and $1700 for TIA
(identiﬁed by ED) (all P<0.01). In the multivariate regression
predicting stroke-related follow-up costs (index plus 12-month
post-index), AF was associated with signiﬁcant increases in
total stroke-related costs among patients with IS (20%), HS
(13%), and TIA (19%) (all P<0.01) (Table 3).
Discussion
In this study, we estimate the direct cost of stroke-related
medical care among patients with AF versus those without AF
using a large payer database. After controlling for potential
confounders, adjusted mean incremental costs (index plus 12-
month post-index) for AF patients were signiﬁcantly higher
than those for non-AF patients, with results from a generalized
linear model demonstrating the statistical signiﬁcance of this
relationship. This study is subject to the general limitations of
basing case ascertainment on ICD-9-CM codes from billing
data, including coding errors and potential underestimation of
event occurrence. We only counted follow-up costs for
medical care that listed stroke/TIA as a diagnosis; also, this
likely underestimates the full costs experienced by patients,
because some stroke-related services may be coded for
speciﬁc complications rather than strictly stroke or TIA.
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O
R
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HHowever, our index hospitalization and post-index stroke-
related cost ﬁndings are consistent with estimates reported
from previous studies using various sources of data.
3,10
While limited data exist on the relationship between AF and
stroke-related costs from a US perspective, multiple published
studies have attempted to evaluate this relationship with non-
US data sources. For instance, a 2008 article published by
Ghatnekar and colleagues evaluated the impact of AF on
stroke-related inpatient costs over a 3-year follow-up period in
Sweden.
11 Due to a higher observed mortality rate during the
index stroke hospitalization, patients with AF had a shorter
mean follow-up period than those without the disease,
resulting in a non-signiﬁcant difference in costs between the
2 cohorts over the full follow-up period. The effect of AF on
stroke-related inpatient costs became statistically signiﬁcant
once only patients surviving the index event were included in
the regression analysis (€818 higher, P<0.01), a criterion also
employed in our study. An analysis of data from the Berlin
Acute Stroke Study also established a signiﬁcant relationship
between the presence of AF and higher total direct costs
within 1 year of an index stroke event (€2982 higher,
P<0.001), with resource use and cost data obtained from a
patient self-report survey.
12 In addition to providing data from
a US perspective, our study adds to this body literature by
providing estimates on stroke-related costs for all compo-
nents of medical care (eg, inpatient, outpatient, rehabilitation)
to third-party payers stratiﬁed by stroke type.
Our ﬁndings provide current estimates ofthe cost ofvarious
stroke types, including ischemic stroke, hemorrhagic stroke,
and TIA. These results demonstrate the high economic burden
of stroke to payers, especially in persons with AF. Therefore,
reducing the risk of AF-related stroke may be important from
both a clinical and economic standpoint. Professional guide-
lines recommend oral anticoagulant therapy for the prevention
of stroke in patients with AF.
13 Data from this analysis will be
useful when evaluating the cost-effectiveness of clinical
interventions designed to prevent stroke among those with
AF, such as new developments in anticoagulant therapy.
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